Plasticell gets funding to develop blood substitute from stem cells – pharmaphorum
pharmaphorum |
Plasticell gets funding to develop blood substitute from stem cells
pharmaphorum Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, has secured £920,000 from the British government’s Innovate UK to create a safe, effective red blood cell substitute for human clinical transfusion. A … |
Gizmodo Australia |
A New Flavour Of CRISPR Could Tackle Some Of The Worst Genetic Diseases
Gizmodo Australia The authors note that CRISPR–Cpf1 may actually be more successful at targeting Duchenne muscular dystrophy, by accessing mutation sites the more unwieldy Cas9 can’t access. Cpf1, they said, could be a powerful new tool in the CRISPR arsenal. Gene-Editing Alternative Corrects Duchenne Muscular DystrophyDrug Discovery & Development CRISPR Corrects Duchenne-Causing MutationsThe Scientist Accurate DNA misspelling correction methodPhys.Org Civil Eats all 34 news articles » |